Biotin-Targeted Au(I) Radiosensitizer for Cancer Synergistic Therapy by Intervening with Redox Homeostasis and Inducing Ferroptosis
Authors:
- 10 June 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (12) , 8401-8415
Abstract
The search for highly selective sensitizers with a novel mechanism for tumor targeting therapy is of considerable interest. In this work, we have developed a series of new biotin-targeted Au(I) complexes. Through systematic biological evaluation and comparison, biotinylated Au(I) complex 3a containing a triphenylphosphine ligand was screened, as it realized both prominent efficient inhibition and selective cytotoxicity to cancer cells, and the effect was better than that of popularly used auranofin. Meanwhile, complex 3a, as a potent radiosensitizer, enhances anticancer effects in vitro and in vivo and has sensitization selectivity. From the action mechanism study, we provide evidence that complex 3a could intervene in redox homeostasis through targeted binding and strong suppression of thioredoxin reductase (TrxR) and induce the ferroptosis death process, enabling it to sensitize tumor cells to radiotherapy. Thus, complex 3a has enormous potential as an efficient and specific radiosensitizing agent in cancer therapy.Keywords
Funding Information
- Nanjing University of Chinese Medicine (2020YLXK010)
- National Natural Science Foundation of China (82002738, 82173684)
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Jiangsu Province Graduate Practice Innovation Program (KYCX20_1490)
- ?Innovative and Entrepreneurial Team? Program of Jiangsu Province
This publication has 40 references indexed in Scilit:
- Effects of redox modulation by inhibition of thioredoxin reductase on radiosensitivity and gene expressionJournal of Cellular and Molecular Medicine, 2012
- Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trialThe Lancet Oncology, 2012
- NHC Gold Halide Complexes Derived from 4,5-Diarylimidazoles: Synthesis, Structural Analysis, and Pharmacological Investigations as Potential Antitumor AgentsJournal of Medicinal Chemistry, 2011
- Benzimidazol-2-ylidene Gold(I) Complexes Are Thioredoxin Reductase Inhibitors with Multiple Antitumor PropertiesJournal of Medicinal Chemistry, 2010
- The status of platinum anticancer drugs in the clinic and in clinical trialsDalton Transactions, 2010
- Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysisNucleic Acids Research, 2010
- Thioredoxin and Cancer: A Role for Thioredoxin in all States of Tumor OxygenationCancers, 2010
- Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studiesMedicinal Research Reviews, 2009
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Analysis of the Cost Effectiveness of Concurrent Cisplatin-Based Chemoradiation in Cervical Cancer: Implications from Five Randomized TrialsGynecologic Oncology, 2000